Generic Onglyza Availability

Last updated on Jun 11, 2025.

Onglyza is a brand name of saxagliptin, approved by the FDA in the following formulation(s):

ONGLYZA (saxagliptin hydrochloride - tablet;oral)

• Manufacturer: ASTRAZENECA AB
  Approval date: July 31, 2009
  Strength(s): EQ 2.5MG BASE (discontinued) ^{[RLD] [AB]}, EQ 5MG BASE (discontinued) ^{[RLD] [AB]}

All of the above formulations have been discontinued.

Is there a generic version of Onglyza available?

A generic version of Onglyza has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Onglyza and have been approved by the FDA:

SAXAGLIPTIN (saxagliptin hydrochloride tablet;oral)

• Manufacturer: AUROBINDO PHARMA
  Approval date: July 31, 2023
  Strength(s): EQ 2.5MG BASE ^[AB], EQ 5MG BASE ^[AB]
• Manufacturer: GLENMARK PHARMS LTD
  Approval date: July 31, 2023
  Strength(s): EQ 2.5MG BASE ^[AB], EQ 5MG BASE ^[AB]
• Manufacturer: MYLAN
  Approval date: July 31, 2023
  Strength(s): EQ 2.5MG BASE ^[AB], EQ 5MG BASE ^[AB]
• Manufacturer: SUN PHARM
  Approval date: July 31, 2023
  Strength(s): EQ 2.5MG BASE ^[AB], EQ 5MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Onglyza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Coated tablet formulation and method
  Patent 7,951,400
  Issued: May 31, 2011
  Inventor(s): Desai; Divyakant S. et al.
  Assignee(s): Bristol-Myers Squibb Company (Princeton, NJ)
  

  A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin ##STR00001## or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.

  Patent expiration dates:

  • November 30, 2028
    
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer